financetom
PBH
financetom
/
Healthcare
/
PBH
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Prestige Consumer Healthcare Inc.PBH
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally.

The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief.

The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products.

It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels.

The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018.

Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Latest News >
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
Dec 9, 2024
05:43 PM EST, 12/09/2024 (MT Newswires) -- Biomea Fusion ( BMEA ) said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a transformative therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer. The investigational therapy demonstrated a favorable safety and tolerability profile...
Roblox Insider Sold Shares Worth $27,698,899, According to a Recent SEC Filing
Roblox Insider Sold Shares Worth $27,698,899, According to a Recent SEC Filing
Dec 9, 2024
05:44 PM EST, 12/09/2024 (MT Newswires) -- David Baszucki, 10% Owner, Director, President & CEO, on December 05, 2024, sold 483,335 shares in Roblox ( RBLX ) for $27,698,899. Following the Form 4 filing with the SEC, Baszucki has control over a total of 1,004,280 shares of the company, with 129,295 shares held directly and 874,985 controlled indirectly. SEC Filing:...
Nanobiotix's NBTXR3 Phase 1 Study Yields Promising Results for Pancreatic Cancer Treatment
Nanobiotix's NBTXR3 Phase 1 Study Yields Promising Results for Pancreatic Cancer Treatment
Dec 9, 2024
05:44 PM EST, 12/09/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said late Monday it completed the dose escalation and expansion phases of a phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with advanced or borderline resectable pancreatic cancer. The study showed promising results, with a 23-month median overall survival from diagnosis in 22 patients, compared to a 19.2-month historical...
Invesco Reports 4.8% Gain in November AUM
Invesco Reports 4.8% Gain in November AUM
Dec 9, 2024
05:43 PM EST, 12/09/2024 (MT Newswires) -- Invesco ( IVZ ) reported preliminary assets under management late Monday of $1.857 trillion at the end of November, up 4.8% month over month. The company said favorable market returns positively affected AUM by $52 billion and foreign exchange decreased it by $3 billion, respectively. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved